Metabolic Nutrition ships out products that help people shape up. Products include meal replacement shake powders, weight loss supplements, and anti-oxidant formulations. Its weight loss division offers products such as SyneDrex and Phenolox, which are metabolism stimulators, and Ametrol, a carbohydrate inhibitor. Sports performance offerings includes meal replacement Advantage and stamina enhancer TAG. The health and wellness division offers customers vitamin supplement Quidprim and immune system booster Stipatore, among other formulations. Metabolic Nutrition's products are sold in select health food stores; the company also takes orders through its Web site and over the phone.

The US subsidiary of pharmaceuticals and materials giant Bayer AG (or Bayer Group), Bayer Corporation operates through three divisions and an internal services company. Bayer Corporation handles Bayer Group's US operations in three segments: Bayer HealthCare (pharmaceuticals, animal health, and over-the-counter medicines), MaterialScience (plastics, coatings, and polyurethanes), and Bayer CropScience (herbicides, fungicides, and insecticides). The internal services unit, Bayer Corporate and Business Services, handles administrative, technology, human resources, legal, and procurement functions for the Bayer Group's US operations.

Emergent BioSolutions Inc. company was founded in 1998 and is based in Rockville, Maryland. mergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The company's earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency.

Diversa Limited company has developed biosensor technology, drawing on work from the fields of biotechnology, nanotechnology, and electronics. Its primary technology is the Ion Channel Switch, a biosensing device. The Ion Channel Switch, or ICS, technology was developed using a membrane that acts as a switch, triggering an electrical current in the presence of particular molecules. Diversa plans to use the technology in point-of-care diagnostic products. The ICS was developed from research done by the Australian Membrane and Biotechnology Research Institute (AMBRI), the University of Sydney, and others.

Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.

Inspire Pharmaceuticals was founded in 1993 and is based in Durham, North Carolina. Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease in adults and children in the United States. Its product candidates in clinical development include Prolacria, a diquafosol tetrasodium for the treatment of dry eye disease in phase III; denufosol tetrasodium, an inhaled product for the treatment of cystic fibrosis in phase III; AzaSite for the treatment of blepharitis, which is in phase II; and INS115644 and INS117548, which are in phase I clinical trial for the treatment of glaucoma or ocular hypertension. The company has a joint license agreement with Allergan, Inc. to develop and commercialize Prolacria; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the U.S. and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia.

Rosemont Pharmaceuticals keeps the medicine flowing. The drugmaker specializes in generic oral liquid formulations of drugs for patients who have difficulty swallowing pills and capsules, oftentimes elderly patients or young children. It makes more than 90 licensed products under its own brand -- including antibiotics, cardiovascular treatments, analgesics, and corticosteroids -- and distributes them primarily to hospitals, primary care centers, and pharmacies in the UK. It also makes custom liquid formulations of unlicensed drugs (called "Specials") and offers contract manufacturing services. In 2006 Close Brothers backed a management buy-out of Rosemont, which had been a subsidiary of Savient Pharmaceuticals.

The Italian subsidiary of Swiss drug maker Roche manufactures all of the company's most successful medications -- hepatitis B and C drug Pegasys, cancer drugs Herceptin and Avastin, and MabThera, for non-Hodgkin lymphoma. Roche S.p.A.'s business is roughly 40% oncology and hematology, 30% specialty care (Pegasys, Neorecormon, Copegus), and 30% primary care (analgesics, antibiotics). Its 700,000-square-foot production facility in Segrate, a town near Milan in northern Italy, produces almost 1,400 tons of medication every year, about 60% of which is exported across Europe.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.